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Summary Background: It is well documented that the perception of dyspnea (POD),
subjectively reported by patients, is an important index used to guide treatment. The
severity of dyspnea following methacholine-induced bronchoconstriction and added
mechanical loads is increasing in popular. No formal attention has been addressed to
the reduction in dyspnea following bronchodilators. Study objective: To investigate if
the magnitude of dyspnea perceived by a subject is independent on the direction
(e.g., bronchoconstriction or bronchodilation) of the change in airway resistance.
Methods: The POD was measured in 26 mild–moderate asthmatic patients following
bronchodilation, using b2-agonists, and following bronchoconstriction, induced by
methacholine challenge, to almost the same magnitude. Results: The increase in
forced expiratory volume in 1 s (FEV1), 30min after the inhalation of b2-agonist
(mean7SEM 22.370.8%), was associated with a statistically significant decrease
(Po0:005) in the POD. The mean decrease in FEV1 following methacoline challenge,
was 2370.7% and was followed by a statistically significant increase (Po0:005) in the
POD. The magnitude of the decrease in the POD following albuterol was almost
identical to the magnitude of the increase in the POD following methacholine.
Conclusions: In stable mild–moderate asthmatic patients, the changes in the
magnitude of dyspnea, perceived by a subject, is independent on the direction of
the change in the FEV1.
r 2003 Elsevier Ltd. All rights reserved.
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Introduction
In the management of bronchial asthma, the
subject’s perception of dyspnea (POD) (breathing
discomfort) is an important index used to guide
treatment. However, when asthmatic patients
complain of dyspnea, usually there is no good
correlation between the symptoms and the degree
of airway obstruction.1
There is considerable variability between symp-
toms and airway obstruction, probably due to
change in lung volume, speed of bronchoconstric-
tion, anxiety level, duration of asthma and age,2–5
attitudes, expectations and personality traits.6,7
Other influences may be related to the technique
used to measure the POD. The methods used to
assess the perception of breathlessness include
several techniques. It is measured following
antigen, exercise, histamine, or methacholine-
induced-bronchoconstriction,1,8,9 or during exter-
nally added loading.10,11 Previous studies have
shown that some factors which are related to the
method of inducing bronchoconstriction can affect
POD related to bronchoconstriction. Among these
are hyperinflation of the lung and its unfavorable
consequences on respiratory muscle function,12,13
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the speed of bronchoconstriction2–5 and the effects
of the various therapeutic agents that may affect
the airway system, in addition to just increasing the
Raw.14
We prefer to use the method of adding external
threshold loads, as was used by Larsen et al.15 This
method of breathing against incremental threshold
loads, which is flow-independent, was found to be
reliable and reproducible. Kikuchi et al.10 de-
scribed a similar method, using added resistance
instead of added threshold loads.
In spite of a better understanding of the
pathogenesis of asthma and its improved treat-
ments, morbidity and mortality of asthma do not
decrease in most countries.16 It emphasizes the
need to closely monitor the state of the patients’
disease, the response to anti-asthma drugs, to
measure the POD following treatment and to assess
the change in dyspnea associated with bronchodi-
lating therapy. Bronchodilation is accompanied by a
decrease in airway resistance and by the with-
drawal of the stimulus for dyspnea. However, there
is no data as to whether the magnitude of dyspnea
perceived by a subject should depend on the
direction of the change in airway function.
The present study was carried out in order to
investigate the effect of bronchodilation on the
POD of asthmatic patients and to compare the
result to the more common test of measuring
the POD following bronchoconstriction. We have
speculated that if the magnitude of dyspnea
perceived by a subject is independent on the
direction (e.g., bronchoconstriction or bronchodi-
lation) of the change in airway resistance, then the
response to bronchodilation may serve as a good
test to identify patients with low POD.
Methods
Twenty-six asthmatic patients, with mild persis-
tent-moderate asthma, attending the asthma
clinic, were recruited for the study. All symptoms
of episodic wheezing, cough, and shortness of
breath responding to bronchodilators, and rever-
sible airflow obstruction (X15%) documented in at
least one previous pulmonary function study.17 All
patients were in a stable state and had mild
persistent-moderate asthma (defined by forced
expiratory volume in 1 s (FEV1)460% ***of pre-
dicted normal values studied in the morning before
bronchodilators). All were on inhaled corticoster-
oids and rescue b2-agonists, but were asked to
withhold inhaled corticosteroids 1 week before
entering the study, and bronchodilators 12 h before
each visit. The study protocol was approved by the
Medical Ethical Committee of the hospital and
informed consent was obtained from each patient.
Patients who stopped inhaling steroids were in-
structed to consult the investigators in case of
exacerbation of their asthma.
Study design
Visit 1: The purposes of visit 1 were verification of
inclusion criteria and familiarization with testing
procedures.
Visit 2: Spirometry and the POD were measured,
in all patients, before and 30min following inhala-
tion of two puffs of albuterol (200 mg) by metered
dose inhaler.
Visit 3: Spirometry and the POD were measured,
before and following bronchial challenge with
methacholine.
Tests
Spirometry
The forced vital capacity and the FEV1 were
measured 3 times on a computerized spirometer
(Compact, Vitalograph, Buckingham, England) and
the best trial is reported.
Perception of dyspnea
The sensation of dyspnea was measured while the
subject breathed through a device similar to that
proposed by Nickerson and Keens.18 Subjects were
instructed to breath spontaneously. Subjects in-
spired through a two-way Hans–Rudolph valve,
whose inspiratory port was connected to a chamber
and plunger to which weights could be added
externally. The subjects breathed against a load in
order to achieve mouth pressure of 0 (no load), 5,
10, 20, and 30 cm H2O. After breathing for 1min in
each level of load, in a protocol similar to the one
previously described by Kikuchi and colleagues,10
using a method recently published by Larson and
colleagues15 with the same device as ours, the
subjects rated the sensation of difficulty in breath-
ing (dyspnea) using the modified Borg scale.19 The
subjects were required to choose a number
between 0 and 10 that represented the level of
the perceived breathing difficulty with 0 indicating
no difficulty and 10 the maximum difficulty.
Bronchial challenge test
The patients were administered a methacholine
aerosol inhalation test according to a standardized
tidal breathing procedure.20 Two-fold increasing
concentrations of methacholine were inhaled
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during tidal breathing for 2min (0.03–128mg/ml)
at 5min intervals. The test was stopped:
(a) following a decrease of 410% in the FEV1, for
those patients with an increase of o20% in
their FEV1 after albuterol.
(b) following a decrease of 420% in the FEV1, for
those patients with an increase of 20–25% in
their FEV1 after albuterol.
(c) following a decrease of 430% in the FEV1, for
those patients with an increase of 425% in
their FEV1 after albuterol.
Data analysis
The results are expressed as means7SEM. The POD
during the incremental load challenge was ana-
lyzed by calculating the linear regression slope
between the changes in the Borg score and the
added load. Correlations were assessed by calcu-
lating Spearman correlation coefficients. Compar-
isons of lung function and dyspnea score were
carried out using the two-way repeated measures
analysis of variance.
Results
Twenty-six patients were recruited for the study.
The mean7SEM FEV1 of the patients, before and
30min following the inhalation of the b2-agonist
(visit 2) are summarized in Table 1. The individual
data is shown in Table 2. In two patients, the
increase in FEV1 was o15%. However, all were
asthmatics and had shown reversibility of airflow
obstruction in at least one previous pulmonary
function study. It was 420% but o25% in 15
patients, and it was 425% in the remaining six
patients. The mean7SEM increase in FEV1 was
22.770.8% (range 9–36%), compared to baseline,
following albuterol.
The increase in FEV1, 30min after the inhalation
of b2-agonist, was associated with a statistically
significant decrease (Po0:005) in the mean Borg
score during breathing against load (Fig. 1). There
was a good correlation (R2 ¼ 0:341) between the
individual increase in FEV1 and the decrease in the
Borg score (Fig. 2). No patient has fatigued during
the test and all patients completed the test even at
the highest load.
The baseline FEV1 during visit 3 was reproducible
and almost identical to the one measured during
visit 2. The mean decrease in FEV1 following
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Table 1 Characteristics of patients with asthma, before, following albuterol and following methacholine challengea.
No. Age (yr) Sex (M/F) FEV1 (% of pred.)
Albuterol Methacholine
Baseline After Baseline After
26 37.274.3 16/10 7174.0 8774.9 7474.2 5773.8
aMean7SEM.
Table 2 Individual changes in the POD following
albuterol and following methacholine challenge.
Subject
No.
Albuterol Methacholine
DFEV1 DPOD DFEV1(%) DPOD
1 22 5.5 24 5.0
2 20 5.7 23 6.0
3 20 5.9 25 6.8
4 20 6.0 23 6.4
5 20 7.0 24 6.7
6 20 6.5 22 7.2
7 22 6.5 25 5.5
8 22 6.1 21 6.4
9 21 6.1 20 6.8
10 21 6.2 23 6.9
11 24 7.0 24 6.6
12 24 6.4 25 5.9
13 24 6.0 25 7.1
14 23 6.9 25 6.4
15 23 6.4 20 5.7
16 25 6.6 22 6.3
17 27 6.7 34 5.8
18 30 6.8 28 6.0
19 30 7.2 34 6.5
20 32 6.7 29 6.1
21 36 7.0 31 6.5
22 9 5.7 17 6.2
23 12 5.5 10 6.0
24 18 6.0 13 5.8
25 18 6.3 19 6.9
26 16 5.6 12 6.0
Mean7SEM22.770.86.3270.423.070.96.2970.5
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methacoline challenge, during visit 3, was 23%
(range 12–34%). The decrease in FEV1 following the
methacholine challenge was associated with a
statistically significant increase (Po0:005) in the
mean Borg score during breathing against load
(Fig. 1). However, there was no good correlation
(R2 ¼ 0:004) between the individual decrease in
FEV1 and the increase in the Borg score.
The mean7SEM decrease of the POD (the sum of
all scoresFat 0, 5, 10, 20 and 30 cm H2O) following
albuterol and the mean increase of the POD
following methacholine test, are shown in Fig. 3.
The mean7SEM decrease of the POD following
albuterol was 6.3270.4, while the mean increase
following methacholine was 6.2970.5.
The individual changes in the FEV1 and the POD
following albuterol and methacholine are pre-
sented in Table 2.
Discussion
In the present study we have shown that, in stable
asthmatic patients, the changes in the magnitude
of dyspnea perceived by a subject is independent
on the direction (e.g., bronchodilation or bronch-
oconstriction) of change of the FEV1.
Breathlessness associated with bronchoconstric-
tion in asthmatic subjects originates in complex
and not yet fully understood mechanism. Increase
in the resistive work of breathing is playing some
role in causing breathlessness21,22 through activa-
tion of respiratory muscles. It has been shown that
there is a close relationship between the sensation
of breathlessness and respiratory muscle force,
both in normal subjects and in patients with COPD
with severe lung function impairment.13 Hyperin-
flation of the lung and higher intrathoraxic pres-
sure, resulting from an increased airway resistance
may also contribute to respiratory discomfort.23 In
addition, non-mechanical stimuli such as airway C
fibers activated by inflammatory mediators may
contribute to the POD,23,24 and it was shown that
airway inflammation and the integrity of the airway
epithelium influence the perception of induced
bronchoconstriction.25 Therefore, it is not surpris-
ing that most published studies have found no good
correlation between the initial estimation of
ARTICLE IN PRESS
Figure 2 Relationship between the changes in FEV1 and
the changes of the Borg score following inhalation of
albuterol.
Figure 1 Mean7SEM baseline POD of the asthmatic
patients, following increase in FEV1 after the inhalation
of b2-agonist, and following the decrease in FEV1 after
the methacholine challenge.
Figure 3 Mean7SEM decrease of the POD (the sum of all
scores) following albuterol and the mean increase of the
POD following methacholine test.
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dyspnea and the FEV1. A recent study
26 has shown
that the features or structures of breathing
discomfort uncovered in patients are not simply
dependent on the presence of underlying patho-
physiology or on a specific disease condition.
Breathlessness in each condition results from a
different composite of sensations. Three attributes
of breathing discomfort were revealed through
application of MDS algorithms to dissimilarity
ratings: disturbances in the mechanics of breath-
ing; alterations in the drive to breathe; and
difficulty breathing and phase of respiration.
The POD in asthma is usually studied during
spontaneous attacks or during smooth muscle
against bronchoprovocation like histamine and
methacholine. These studies compare indexes of
dyspnea rated first when the patient is in stable
condition and rated again after the production of a
20% decline of FEV1. Those studies have the
advantages of mimicking faithfully mechanical
derangements, sensations and qualitative aspects
of dyspnea during a spontaneous asthmatic at-
tack,12 and the bronchoconstriction is easily rever-
sible. It is worth mentioning that despite a close
linear relationship between the decrease in FEV1
and the increase in POD, there is a considerable
variation in the severity of breathlessness for any
particular degree of airflow obstruction.1 Measuring
POD during external mechanical loading (resistive,
elastic or threshold) less accurately simulate the
mechanical characteristics of an asthma attack.27
However, it was previously shown that the imposed
inspiratory threshold load is a good predictor for
explaining the variability of the perceived dys-
pnea.28 In addition, this test is easy to perform, it
provides a linear correlation, with several mea-
surements, and is highly reproducible.
In a recent study performed by our group,29 it
was found that about 15% of the referral subjects
with asthma had low POD, when compared to
healthy matched subjects. Patients with low POD
had statistically significant more ER visits, hospita-
lizations, near-fatal asthma and deaths during the
follow-up period. We concluded that reduced POD
might predispose patients to life-threatening at-
tack and that measurement of the POD should be
performed at least once in all asthma patients to
identify those at high risk for a fatal attack.
Usually, to investigate the ability of the patient
to perceive respiratory sensation the bronchial
provocation test is used. However, this test has
some disadvantages. Although the assessment of
the relation between the change in airway resis-
tance and the respiratory sensation requires an
adequate number of indexes over a wide range of
stimulus intensity, it must be performed within
ethical boundaries and often only two or three
concentrations of methacholine can be adminis-
tered. Furthermore, the provocation test is time
consuming and is much less comfortable for the
patient.
There are only very few studies which tested the
POD before and following bronchodilators.29 In this
case, the change in dyspnea is brought about by a
decrease, rather than an increase, in airway
resistance and lung volume. In addition to the need
for identifying patients with low POD, it is some-
times necessary to evaluate the relief in dyspnea
associated with bronchodilating therapy. Should
the change in the magnitude of dyspnea perceived
by a subject depend on the direction (e.g,
bronchoconstriction or bronchodilation) of the
change in airway resistance? Although our study
shows that both bronchoconstriction and broncho-
dilation, to the same magnitude, are equally
perceived by the patients, but in the opposite
direction, as a group, it should be mentioned that
there was no good correlation between the
decrease in FEV1 and the increase in POD following
the methacholine challenge. This may indicate
different mechanisms behind the breathing dis-
comfort of asthmatics. However, it seems that in
patients with asthma, assessing the POD before and
following bronchodilation, in order to define those
with low POD, or to evaluate the anti-asthma
treatment, is as valuable as assessing it following
induction of brochospasm. It may be measured
before and following bronchodilators, with, or
without, the application of external load. The
addition of the external loads test provides us with
more reproducible and comparable indexes of
dyspnea than a test that just assesses two indexes,
one before and one following the stimulus.
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